Results 11 to 20 of about 331,966 (252)

Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology [PDF]

Indian Journal of Ophthalmology
Anti-vascular endothelial growth factor (VEGF) therapy has emerged as an important adjunct in the management of uveitis, particularly for complications driven by vascular permeability and ischemia, such as uveitic macular edema, inflammatory choroidal ...
Ankush Kawali, Sai Bhakti Mishra, Padmamalini Mahendradas, Rohit Shetty   +3 more
doaj   +2 more sources

Anti-vascular endothelial growth factor in ophthalmology

Indian Journal of Ophthalmology, 2009
Sinha Rajesh, Choudhary Sunil, Sinha Subijoy, Vashisht Nagender, Kumar Chandrashekhar   +4 more
doaj   +2 more sources

Anti-vascular endothelial growth factor for neovascular glaucoma [PDF]

Cochrane Database of Systematic Reviews, 2009
Neovascular glaucoma (NVG) is a potentially blinding secondary glaucoma. It is caused by the formation of abnormal new blood vessels which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) agents are specific inhibitors of the primary mediators of neovascularization.
Arathi, Simha, Andrew, Braganza, Lekha, Abraham, Prasanna, Samuel, Kristina, Lindsley   +4 more
openaire   +4 more sources

Biomarkers for anti‑vascular endothelial growth factor drugs

Oncology Letters, 2022
Angiogenesis is regulated by interactions between vascular endothelial growth factors (VEGFs) and VEGF receptors. VEGF-A, VEGF-D, placental growth factor (PlGF) and plasminogen activator inhibitor-1 (PAI-1) have tumor angiogenic activity. VEGF-A and PAI-1 levels in the blood may impact the activity of bevacizumab, and VEGF-D levels may similarly ...
Kuriyama, Sho, Yamada, Takeshi, Matsuda, Akihisa, Takahashi, Goro, Iwai, Takuma, Takeda, Kohki, Ueda, Koji, Miyasaka, Toshimitsu, Yokoyama, Yasuyuki, Shinji, Seiichi, Sonoda, Hiromichi, Ohta, Ryo, Yonaga, Kazuhide, Kanaka, Shintaro, Yoshida, Hiroshi   +14 more
openaire   +2 more sources

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY

Retina, 2022
Background/Purpose: Anti–vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic ...
Kaiser, Peter K., Schmitz-Valckenberg, Marc Steffen, Holz, Frank G.   +2 more
openaire   +2 more sources

Anti-vascular endothelial growth factor for neovascular glaucoma

Cochrane Database of Systematic Reviews, 2023
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Rittiphairoj, Thanitsara, Roberti, Gloria, Michelessi, Manuele   +2 more
openaire   +3 more sources

Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report

Journal of Medical Case Reports, 2021
Background Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat macular diseases, including diabetic macular edema.
Miwako Yoshimoto, Nobuhiko Takeda, Takayuki Yoshimoto, Shun Matsumoto   +3 more
doaj   +1 more source

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma [PDF]

Journal of Clinical Oncology, 2015
Treatment of glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need in oncology. Historically, cytotoxic treatments provided little durable benefit, and tumors recurred within several months.
Lu-Emerson, Christine, Duda, Dan G, Emblem, Kyrre E, Taylor, Jennie W, Gerstner, Elizabeth R, Loeffler, Jay S, Batchelor, Tracy T, Jain, Rakesh K   +7 more
openaire   +4 more sources

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]

Cochrane Database of Systematic Reviews, 2014
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of
Martinez-Zapata M. J., Salvador I., Marti-Carvajal A. J., Pijoan J. I., Cordero J. A., Ponomarev D., Kernohan A., Sola I., Virgili G.   +8 more
openaire   +7 more sources

Debate on the various anti-vascular endothelial growth factor drugs

Indian Journal of Ophthalmology, 2008
Khalili Mohammad, Hosseini Hamid
doaj   +3 more sources